Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients

Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients

Xiang Wu,1,2 Qing-Jiang Xu,1,2 Ping-Zhou Chen,1,2 Chen-Bo Yu,1,2 Lie-Fu Ye,1,2 Tao Li1,2 1Provincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, People’s Republic of China; 2Department of Urology, Fujian Provincial Hospital, Fuzhou 350001, People’s Repu...

Full description

Bibliographic Details
Main Authors:	Wu X, Xu QJ, Chen PZ, Yu CB, Ye LF, Li T
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-06-01
Series:	Pharmacogenomics and Personalized Medicine
Subjects:	abiraterone androgens castration resistance prostate cancer cyp17a1 cyb5a
Online Access:	https://www.dovepress.com/association-between-cyp17a1-cyb5a-polymorphisms-and-efficacy-of-abirat-peer-reviewed-article-PGPM

Similar Items

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Moritz Binder, et al.
Published: (2016-07-01)

Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
by: Zhenyu Yang, et al.
Published: (2021-08-01)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
by: Takashi Nagai, et al.
Published: (2018-03-01)

Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma
by: R Nandha
Published: (2012-01-01)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
by: Gustavo Werutsky, et al.
Published: (2019-05-01)

Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
by: Ya V Gridneva, et al.
Published: (2014-09-01)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
by: Luca Cindolo, et al.
Published: (2017-11-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01)

Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular Dynamics
by: Fei Xiao, et al.
Published: (2015-01-01)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
by: Yoshinori Yanai, et al.
Published: (2019-07-01)

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
by: Shinichi Sakamoto, et al.
Published: (2019-04-01)

Art-Id/Cyb-Id
by: Josep Giribet
Published: (2007-01-01)

Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial
by: Henrik Suttmann, et al.
Published: (2020-09-01)

The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice
by: Celeste Nicola, et al.
Published: (2021-07-01)

The first experience in using abiraterone acetate in patients with castration-refractory prostate cancer
by: L. M. Rapoport, et al.
Published: (2015-11-01)

Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)
by: Javier Puente, et al.
Published: (2019-08-01)

A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients
by: Aloysius James, et al.
Published: (2018-01-01)

Abiraterone Acetate Withdrawal Syndrome: Does It Exist
by: Hélène Gauthier, et al.
Published: (2012-07-01)

Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy
by: Laura Dupuy, et al.
Published: (2013-06-01)

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
by: Carsten-Henning Ohlmann, et al.
Published: (2017-10-01)

CYP17A1 Maintains the Survival of Glioblastomas by Regulating SAR1-Mediated Endoplasmic Reticulum Health and Redox Homeostasis
by: Hong-Yi Lin, et al.
Published: (2019-09-01)

Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study
by: Jin-Ge Zhao, et al.
Published: (2018-01-01)

Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency
by: Mónica Fernández-Cancio, et al.
Published: (2018-04-01)

The efficacy of abiraterone acetate in treating Taiwanese chemo-refractory metastatic castration-resistant prostate cancer patients
by: Tony Wu, et al.
Published: (2016-12-01)

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment
by: Emmy Boerrigter, et al.
Published: (2021-09-01)

Replacing prednisolone with dexamethasone to overcome the resistance to abiraterone in castration-resistant prostate cancer: a clinical case
by: A. A. Meshcheryakov, et al.
Published: (2020-07-01)

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience
by: Yang Liu, et al.
Published: (2021-01-01)

A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
by: A. V. Kondrashina, et al.
Published: (2018-05-01)

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
by: España S, et al.
Published: (2020-10-01)

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
by: Castellan P, et al.
Published: (2018-12-01)

A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer
by: Amit Joshi, et al.
Published: (2020-01-01)

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study
by: Martin Boegemann, et al.
Published: (2019-01-01)

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial
by: Kouji Izumi, et al.
Published: (2017-10-01)

Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
by: Wei Zhang, et al.
Published: (2017-01-01)

Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report
by: Luigi Rossi, et al.
Published: (2021-03-01)

Very Fast Recovery of Acute Disseminated Intravascular Coagulation with Abiraterone Acetate in a Patient with Bone Metastases from Castrate-Resistant Prostate Cancer
by: Hélène Gauthier, et al.
Published: (2014-09-01)

Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
by: Liancheng Fan, et al.
Published: (2018-12-01)

Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
by: El-Amm J, et al.
Published: (2017-07-01)

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer
by: Hung-Ming Lam, et al.
Published: (2018-05-01)